

Rab K Prinjha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3672348/publications.pdf>

Version: 2024-02-01

109
papers

14,442
citations

31976

53
h-index

26613

107
g-index

110
all docs

110
docs citations

110
times ranked

20855
citing authors

#	ARTICLE	IF	CITATIONS
1	Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2262-2287.	6.4	14
2	Selective inhibitors of bromodomain <scp>BD1</scp> and <scp>BD2</scp> of <scp>BET</scp> proteins modulate radiation-induced profibrotic fibroblast responses. <i>International Journal of Cancer</i> , 2022, , .	5.1	3
3	Combined noncanonical NF- κ B agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	17
4	Bromodomain Inhibitors Modulate Fc γ R-Mediated Mononuclear Phagocyte Activation and Chemotaxis. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	2
5	Bromodomain factor 5 is an essential regulator of transcription in <i>Leishmania</i> . <i>Nature Communications</i> , 2022, 13, .	12.8	8
6	Bromodomain proteins regulate human cytomegalovirus latency and reactivation allowing epigenetic therapeutic intervention. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	25
7	Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3249-3281.	6.4	19
8	BRD4 methylation by the methyltransferase SETD6 regulates selective transcription to control mRNA translation. <i>Science Advances</i> , 2021, 7, .	10.3	23
9	Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded Library Technology Screening Hit. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10806-10833.	6.4	31
10	Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10711-10741.	6.4	17
11	Identification of a Series of <i>N</i> -Methylpyridine-2-carboxamides as Potent and Selective Inhibitors of the Second Bromodomain (BD2) of the Bromo and Extra Terminal Domain (BET) Proteins. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10742-10771.	6.4	14
12	Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10772-10805.	6.4	17
13	IFN- γ Drives Human Monocyte Differentiation into Highly Proinflammatory Macrophages That Resemble a Phenotype Relevant to Psoriasis. <i>Journal of Immunology</i> , 2021, 207, 555-568.	0.8	15
14	Optimization of Naphthyridones into Selective TATA-Binding Protein Associated Factor 1 (TAF1) Bromodomain Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1308-1317.	2.8	4
15	Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 12200-12227.	6.4	26
16	Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. <i>Nature Cancer</i> , 2021, 2, 1002-1017.	13.2	99
17	Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. <i>Nature Cancer</i> , 2021, 2, 1002-1017.	13.2	23
18	Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment Screening. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 714-746.	6.4	45

#	ARTICLE	IF	CITATIONS
19	Epigenetic Regulation of T Cell Memory: Recalling Therapeutic Implications. Trends in Immunology, 2020, 41, 29-45.	6.8	46
20	Design and Synthesis of a Highly Selective and <i>In Vivo</i> -Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins. Journal of Medicinal Chemistry, 2020, 63, 9070-9092.	6.4	40
21	GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins. Journal of Medicinal Chemistry, 2020, 63, 9045-9069.	6.4	59
22	The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor. Journal of Medicinal Chemistry, 2020, 63, 9093-9126.	6.4	41
23	Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype. Journal of Medicinal Chemistry, 2020, 63, 9020-9044.	6.4	38
24	Application of Atypical Acetyl-lysine Methyl Mimetics in the Development of Selective Inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains. Journal of Medicinal Chemistry, 2020, 63, 5816-5840.	6.4	21
25	Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science, 2020, 368, 387-394.	12.6	274
26	Histone H3K27me3 demethylases regulate human Th17 cell development and effector functions by impacting on metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6056-6066.	7.1	61
27	GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family. ACS Medicinal Chemistry Letters, 2020, 11, 1581-1587.	2.8	25
28	Optimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode. Journal of Medicinal Chemistry, 2020, 63, 5212-5241.	6.4	14
29	A Qualified Success: Discovery of a New Series of ATAD2 Bromodomain Inhibitors with a Novel Binding Mode Using High-Throughput Screening and Hit Qualification. Journal of Medicinal Chemistry, 2019, 62, 7506-7525.	6.4	19
30	An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell, 2019, 36, 385-401.e8.	16.8	359
31	Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. Nature Communications, 2019, 10, 2723.	12.8	126
32	Advancements in the Development of non-BET Bromodomain Chemical Probes. ChemMedChem, 2019, 14, 362-385.	3.2	36
33	Signaling function of PRC2 is essential for TCR-driven T cell responses. Journal of Experimental Medicine, 2018, 215, 1101-1113.	8.5	40
34	Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain. Journal of Medicinal Chemistry, 2018, 61, 4317-4334.	6.4	94
35	BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo. Antiviral Research, 2018, 154, 158-165.	4.1	16
36	Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors. Cancer Cell, 2018, 33, 274-291.e8.	16.8	58

#	ARTICLE	IF	CITATIONS
37	Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells. <i>Journal of Biological Chemistry</i> , 2018, 293, 2422-2437.	3.4	72
38	Multiplexed Proteome Dynamics Profiling Reveals Mechanisms Controlling Protein Homeostasis. <i>Cell</i> , 2018, 173, 260-274.e25.	28.9	186
39	BET Inhibition Improves NASH and Liver Fibrosis. <i>Scientific Reports</i> , 2018, 8, 17257.	3.3	27
40	SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. <i>Nature Communications</i> , 2018, 9, 5378.	12.8	60
41	Aiming to Miss a Moving Target: Bromo and Extra Terminal Domain (BET) Selectivity in Constrained ATAD2 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8321-8336.	6.4	17
42	Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach. <i>ACS Chemical Biology</i> , 2018, 13, 2862-2867.	3.4	118
43	Influenza virus infection causes global RNAPII termination defects. <i>Nature Structural and Molecular Biology</i> , 2018, 25, 885-893.	8.2	48
44	The Epigenetics of Autoimmunity and Epigenetic Drug Discovery. , 2018, , 297-320.		0
45	Inhibition of BET Proteins Reduces Right Ventricle Hypertrophy and Pulmonary Hypertension Resulting from Combined Hypoxia and Pulmonary Inflammation. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2224.	4.1	10
46	Drawing on disorder: How viruses use histone mimicry to their advantage. <i>Journal of Experimental Medicine</i> , 2018, 215, 1777-1787.	8.5	37
47	Click chemistry enables preclinical evaluation of targeted epigenetic therapies. <i>Science</i> , 2017, 356, 1397-1401.	12.6	120
48	Immune disease-associated variants in gene enhancers point to BET epigenetic mechanisms for therapeutic intervention. <i>Epigenomics</i> , 2017, 9, 573-584.	2.1	37
49	Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 695-709.	6.4	70
50	Muscle hypertrophy in hypoxia with inflammation is controlled by bromodomain and extra-terminal domain proteins. <i>Scientific Reports</i> , 2017, 7, 12133.	3.3	2
51	Progress in the Development of non-BET Bromodomain Chemical Probes. <i>ChemMedChem</i> , 2016, 11, 477-487.	3.2	40
52	Interrogating the Druggability of the 2-Oxoglutarate-Dependent Dioxygenase Target Class by Chemical Proteomics. <i>ACS Chemical Biology</i> , 2016, 11, 2002-2010.	3.4	36
53	Structural analysis of human KDM5B guides histone demethylase inhibitor development. <i>Nature Chemical Biology</i> , 2016, 12, 539-545.	8.0	155
54	BET bromodomain inhibition promotes neurogenesis while inhibiting gliogenesis in neural progenitor cells. <i>Stem Cell Research</i> , 2016, 17, 212-221.	0.7	38

#	ARTICLE	IF	CITATIONS
55	A Chemical Probe for the ATAD2 Bromodomain. <i>Angewandte Chemie</i> , 2016, 128, 11554-11558.	2.0	10
56	A Chemical Probe for the ATAD2 Bromodomain. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 11382-11386.	13.8	67
57	Epigenetic drug discovery: breaking through the immune barrier. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 835-853.	46.4	136
58	GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 552-557.	2.8	54
59	Clinical progress and pharmacology of small molecule bromodomain inhibitors. <i>Current Opinion in Chemical Biology</i> , 2016, 33, 58-66.	6.1	69
60	Functional interdependence of BRD4 and DOT1L in MLL leukemia. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 673-681.	8.2	92
61	The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 422-429.	0.9	134
62	Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1357-1369.	6.4	52
63	Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4- <i>d</i>]pyrimidin-4(3- <i>H</i>)-one Derivatives. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1370-1387.	6.4	62
64	8-Substituted Pyrido[3,4- <i>d</i>]pyrimidin-4(3- <i>H</i>)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1388-1409.	6.4	83
65	Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1410-1424.	6.4	133
66	Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1425-1439.	6.4	177
67	Bromodomain Proteins Contribute to Maintenance of Bloodstream Form Stage Identity in the African Trypanosome. <i>PLoS Biology</i> , 2015, 13, e1002316.	5.6	58
68	Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. <i>Nature Chemical Biology</i> , 2015, 11, 189-191.	8.0	544
69	Coupling of T cell receptor specificity to natural killer T cell development by bivalent histone H3 methylation. <i>Journal of Experimental Medicine</i> , 2015, 212, 297-306.	8.5	43
70	Preclinical target validation using patient-derived cells. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 149-150.	46.4	46
71	Brd4 bridges the transcriptional regulators, Aire and P-TEFb, to promote elongation of peripheral-tissue antigen transcripts in thymic stromal cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E4448-57.	7.1	62
72	Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6151-6178.	6.4	81

#	ARTICLE	IF	CITATIONS
73	Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 5649-5673.	6.4	75
74	Autism-like syndrome is induced by pharmacological suppression of BET proteins in young mice. <i>Journal of Experimental Medicine</i> , 2015, 212, 1771-1781.	8.5	51
75	BET bromodomain inhibition suppresses transcriptional responses to cytokine- and STAT signaling in a gene-specific manner in human monocytes. <i>European Journal of Immunology</i> , 2015, 45, 287-297.	2.9	67
76	A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression. <i>Journal of Experimental Medicine</i> , 2015, 212, 1551-1569.	8.5	35
77	BET inhibitor resistance emerges from leukaemia stem cells. <i>Nature</i> , 2015, 525, 538-542.	27.8	441
78	Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. <i>Cancer Research</i> , 2015, 75, 5106-5119.	0.9	193
79	Anti-inflammatory Effects of BET Protein Inhibition Through Modulation of Gene Transcription. , 2015, , 199-223.		1
80	Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. <i>Oncotarget</i> , 2015, 6, 21507-21521.	1.8	72
81	Epigenetic modulation of type-1 diabetes via a dual effect on pancreatic macrophages and β^2 cells. <i>ELife</i> , 2014, 3, e04631.	6.0	69
82	The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2795-2805.	0.7	55
83	Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: <sc>IUPHAR</sc> Review 11. <i>British Journal of Pharmacology</i> , 2014, 171, 4981-5010.	5.4	23
84	Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice. <i>Cell</i> , 2014, 158, 989-999.	28.9	337
85	1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 1190-1195.	2.8	78
86	The Discovery of I-BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 Up-Regulator and Selective BET Bromodomain Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 8111-8131.	6.4	159
87	Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. <i>Nature</i> , 2014, 514, 513-517.	27.8	340
88	Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. <i>Blood</i> , 2014, 123, 697-705.	1.4	184
89	The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes. <i>MedChemComm</i> , 2014, 5, 342-351.	3.4	66
90	Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7501-7515.	6.4	271

#	ARTICLE	IF	CITATIONS
91	Remodeling of the Enhancer Landscape during Macrophage Activation Is Coupled to Enhancer Transcription. <i>Molecular Cell</i> , 2013, 51, 310-325.	9.7	616
92	The "Histone Mimicry" by Pathogens. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2013, 78, 81-90.	1.1	14
93	BRD4 Short Isoform Interacts with RRP1B, SIPA1 and Components of the LINC Complex at the Inner Face of the Nuclear Membrane. <i>PLoS ONE</i> , 2013, 8, e80746.	2.5	51
94	BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models. <i>PLoS ONE</i> , 2013, 8, e72967.	2.5	167
95	Selective inhibition of CD4 ⁺ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 14532-14537.	7.1	177
96	Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response. <i>Journal of Experimental Medicine</i> , 2012, 209, 661-669.	8.5	147
97	Suppression of the antiviral response by an influenza histone mimic. <i>Nature</i> , 2012, 483, 428-433.	27.8	269
98	Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2968-2972.	2.2	183
99	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. <i>Nature</i> , 2011, 478, 529-533.	27.8	1,354
100	Lysine methylation of the NF- κ B subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF- κ B signaling. <i>Nature Immunology</i> , 2011, 12, 29-36.	14.5	230
101	Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 3827-3838.	6.4	318
102	Suppression of inflammation by a synthetic histone mimic. <i>Nature</i> , 2010, 468, 1119-1123.	27.8	1,377
103	Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. <i>Human Molecular Genetics</i> , 2009, 18, 767-778.	2.9	419
104	A β 1-42 reduces synapse number and inhibits neurite outgrowth in primary cortical and hippocampal neurons: A quantitative analysis. <i>Journal of Neuroscience Methods</i> , 2008, 175, 96-103.	2.5	51
105	LRRK2 Gly2019Ser penetrance in Arab Berber patients from Tunisia: a case-control genetic study. <i>Lancet Neurology</i> , The, 2008, 7, 591-594.	10.2	172
106	Candidate Single-Nucleotide Polymorphisms From a Genomewide Association Study of Alzheimer Disease. <i>Archives of Neurology</i> , 2008, 65, 45-53.	4.5	443
107	Identification of miRNA Changes in Alzheimer's Disease Brain and CSF Yields Putative Biomarkers and Insights into Disease Pathways. <i>Journal of Alzheimer's Disease</i> , 2008, 14, 27-41.	2.6	835
108	Lipid rafts mediate the interaction between myelin-associated glycoprotein (MAG) on myelin and MAG-receptors on neurons. <i>Molecular and Cellular Neurosciences</i> , 2003, 22, 344-352.	2.2	82

#	ARTICLE	IF	CITATIONS
109	Cloning and functional expression of a human orthologue of rat vanilloid receptor-1. Pain, 2000, 88, 205-215.	4.2	271